RSV treatment market to surge past $9B by 2029

Given the recent approval of two vaccines for respiratory syncytial virus (RSV) as well as other treatments in pipelines, the market for these therapies is expected to reach more than $9B in 2029 from ~$1B today.

An assessment from GlobalData finds that GSK (NYSE:GSK) is set to particularly benefit thanks to its RSV vaccine Arexvy, which was just approved in May in the US and in June in the EU. The consulting and analytics firm sees the UK-based pharma generating ~$2.5B in sales from its shot in 2029.